Jun. 10 at 8:02 PM
$SANA is the leader of Hypoimmune. While others are trying to catch up, and make no mistake there are a few biotechs chomping at the bit to get where we are, they do not have the proof yet that what they are working on will work in human. Others, like ISPC are still in mice models. Will others catch up to Sana? Maybe, even probably, Harr thinks so, but for now we have the lead by a good measure, but there eventually could be competition. As a T1D I'd like to see functional cures from all ASAP. As an investor id like to see sc451 get approved while others are starting to get to ph1 in islets, that way Sana can work on other organs like kidneys while others eventually add to more islets.
https://ca.finance.yahoo.com/news/century-therapeutics-ipsc-reports-positive-182249219.html
